Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR.

J Clin Oncol. 2009 Jan 1;27(1):92-9. doi: 10.1200/JCO.2007.12.3752. Epub 2008 Dec 1.

2.

Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR.

Eur Urol. 2008 Oct;54(4):816-23. doi: 10.1016/j.eururo.2008.01.021. Epub 2008 Jan 15.

PMID:
18243498
3.

Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.

Voog JC, Paulus R, Shipley WU, Smith MR, McGowan DG, Jones CU, Bahary JP, Zeitzer KL, Souhami L, Leibenhaut MH, Rotman M, Husain SM, Gore E, Raben A, Chafe S, Sandler HM, Efstathiou JA.

Eur Urol. 2016 Feb;69(2):204-10. doi: 10.1016/j.eururo.2015.08.027. Epub 2015 Sep 9.

4.

Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31.

Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR.

Cancer. 2007 Dec 15;110(12):2691-9.

5.

Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02.

Smith MR, Bae K, Efstathiou JA, Hanks GE, Pilepich MV, Sandler HM, Shipley WU.

J Clin Oncol. 2008 Sep 10;26(26):4333-9. doi: 10.1200/JCO.2008.16.5845.

6.

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.

Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, Tai KH, Wynne C, D'Este C.

Lancet Oncol. 2011 May;12(5):451-9. doi: 10.1016/S1470-2045(11)70063-8.

PMID:
21440505
7.

Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31.

Souhami L, Bae K, Pilepich M, Sandler H.

J Clin Oncol. 2009 May 1;27(13):2137-43. doi: 10.1200/JCO.2008.17.4052. Epub 2009 Mar 23.

8.

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

Keating NL, O'Malley AJ, Freedland SJ, Smith MR.

J Natl Cancer Inst. 2010 Jan 6;102(1):39-46. doi: 10.1093/jnci/djp404. Epub 2009 Dec 7. Erratum in: J Natl Cancer Inst. 2012 Oct 3;104(19):1518-23.

9.

Editorial comment on: Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

Whelan P.

Eur Urol. 2008 Oct;54(4):823-4. doi: 10.1016/j.eururo.2008.01.022. Epub 2008 Jan 15. No abstract available.

PMID:
18243509
10.

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

Keating NL, O'Malley AJ, Smith MR.

J Clin Oncol. 2006 Sep 20;24(27):4448-56.

PMID:
16983113
11.

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU; Radiation Therapy Oncology Group..

J Clin Oncol. 2003 Nov 1;21(21):3972-8. Erratum in: J Clin Oncol. 2004 Jan 15;22(2):386.

PMID:
14581419
12.

Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer.

Ziehr DR, Chen MH, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, Hyatt AS, Basaria SS, Beard CJ, Beckman JA, Choueiri TK, D'Amico AV, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL.

BJU Int. 2015 Sep;116(3):358-65. doi: 10.1111/bju.12905. Epub 2014 Oct 29.

13.

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D.

Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90.

PMID:
15817329
15.

Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.

Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M.

N Engl J Med. 1997 Jul 31;337(5):295-300.

16.

Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.

Lamb DS, Denham JW, Mameghan H, Joseph D, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Kovacev O, Robertson R, Francis L, Christie D, Spry NA, Tai KH, Wynne C, Duchesne G.

Radiother Oncol. 2003 Sep;68(3):255-67.

PMID:
13129633
17.

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.

Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.

J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24. Epub 2007 Oct 9.

PMID:
17925537
18.

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.

Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D.

Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243-52.

PMID:
11483335
19.

Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1439-44. doi: 10.1016/j.ijrobp.2009.03.034. Epub 2009 Jun 18.

PMID:
19540066

Supplemental Content

Support Center